<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101318</url>
  </required_header>
  <id_info>
    <org_study_id>CP288</org_study_id>
    <nct_id>NCT04101318</nct_id>
  </id_info>
  <brief_title>Investigation of a New Stoma Product for People With a Stoma</brief_title>
  <acronym>CP288</acronym>
  <official_title>Investigation of a New Stoma Product for People With a Stoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CP288 study is an investigation of a non-CE marked stoma product which will be conducted&#xD;
      in the UK, Italy, Netherlands, Germany, and Norway. The study will enroll up to 100 subjects.&#xD;
      The study is a randomized, open-label, comparative study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CP288 study is an investigation of a non-CE marked stoma product which was conducted in&#xD;
      the UK, Italy, Netherlands, Germany, and Norway. The study enrolled 79 subjects. The study is&#xD;
      a randomized, open-label, comparative study. The study is now complete.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Actual">July 17, 2020</completion_date>
  <primary_completion_date type="Actual">July 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Itching</measure>
    <time_frame>12 weeks</time_frame>
    <description>Max Itching score within a week at steady sate based on a new Skin Tool</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Peristomal Skin Complication</condition>
  <arm_group>
    <arm_group_label>New Stoma Baseplate with Protective Layer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Stoma baseplate with Protective layer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1-piece and 2-piece stoma devices already on the market.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>New Stoma Baseplat based on the Sensuro Mio product line.</intervention_name>
    <description>New Stoma Baseplate based on the Sensuro Mio product line. New Baseplate is not named at this point, but has a new protective layer.</description>
    <arm_group_label>New Stoma Baseplate with Protective Layer</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has given informed consent to participate by signing the informed consent signature&#xD;
             form.&#xD;
&#xD;
          2. Has an ileostomy or colostomy with liquid output (defined by a 6-7 on the Bristol&#xD;
             Scale)&#xD;
&#xD;
          3. Currently using a flat product&#xD;
&#xD;
          4. Be at least 18 years of age and have full legal capacity&#xD;
&#xD;
          5. Have had their stoma for at least three months (90 days)&#xD;
&#xD;
          6. Can use a product with a max cut size of 40 mm&#xD;
&#xD;
          7. Has experienced leakage* under the baseplate at least three times within the last 14&#xD;
             days. *leakage defined as output seeping under the baseplate (Appendix 6 -&#xD;
             Classification of leakage)&#xD;
&#xD;
          8. Has symptoms of peristomal skin complications or has peristomal skin complications&#xD;
             defined by at least one of the below&#xD;
&#xD;
               1. Has experienced symptoms of skin complications (itching, burning, pain) within&#xD;
                  the last fourteen days&#xD;
&#xD;
               2. Has experienced red skin in the inner circle (within three cm from stoma edge)&#xD;
                  within the last fourteen days&#xD;
&#xD;
               3. Has skin complication (assessed by Principal Investigator, or delegate) in the&#xD;
                  inner circle (within three cm from stoma edge) of the peristomal area&#xD;
&#xD;
          9. Is able to handle the electronic diary (questionnaire/ photo) themselves.&#xD;
&#xD;
         10. Is able to handle (apply, remove, cut etc.) the product themselves&#xD;
&#xD;
         11. Is willing to not use barrier film or barrier cream during the investigation&#xD;
&#xD;
         12. Is willing and suitable (determined by Principal Investigator, or delegate) to use a&#xD;
             flat custom cut one-piece open or a two-piece open product during the investigation.&#xD;
&#xD;
         13. Is willing to change the product (1pc) or baseplate (2pc) at least every fourth days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is currently receiving or have within the past 60 days received radio-and/or&#xD;
             chemotherapy&#xD;
&#xD;
             - low doses chemotherapy (assessed by Principal Investigator) is allowed for&#xD;
             indications other than cancer.&#xD;
&#xD;
          2. Is currently receiving or have within the past month received topical steroid&#xD;
             treatment in the peristomal skin area, e.g. lotion or spray.&#xD;
&#xD;
               -  Low dose systemic steroid treatment (e.g. inhalation) assessed by the Principal&#xD;
                  Investigator are allowed.&#xD;
&#xD;
               -  Other systemic steroid treatment (e.g. injection, or tablet) are not allowed.&#xD;
&#xD;
          3. Is breastfeeding&#xD;
&#xD;
          4. Is pregnant (based on pregnancy test -urine)&#xD;
&#xD;
          5. Has known hypersensitivity towards any of the products used in the investigation&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nazarena Mazzarro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ragene Saetre</name>
      <address>
        <city>Larvik</city>
        <zip>3256</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 8, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

